LTR Pharma has today announced it has entered into a Comprehensive Co-Development Agreement with Aptar Pharma for SPONTAN® for global markets.

APTAR is a global leader in the design and manufacturing of a broad range of drug and consumer product dosing, dispensing and protection technologies. APTAR has substantial FDA regulatory expertise and its delivery systems are utilized with numerous approved combination products.

The Agreement will combine LTR Pharma’s pharmaceutical development capabilities with Aptar Pharma’s renowned expertise in nasal spray technology, which will support our regulatory pathways and market access for SPONTAN.

LTR Pharma Chairman, Lee Rodne, said:

“We are delighted to enter into a Comprehensive Co-Development Agreement with Aptar Pharma – a respected and experienced partner in our imminent goal to obtain regulatory approval for SPONTAN and to expand its global market reach and impact. As part of this, we will gain access to Aptar’s expertise in the VP7 nasal spray system and related specialised services to support our FDA application process. This de-risks the FDA application process and elevates the profile of LTR Pharma as a long-term partner of a global market innovator, which we anticipate may create opportunities for other products with alternative indications in future.”

Guillaume Brouet, Vice President Analytical Regulatory and Scientific Affairs Aptar Pharma, said:

“We look forward to working closely alongside the LTR Pharma team to support its SPONTAN Nasal Spray application. We have purpose-designed facilities and experienced personnel to ensure a successful partnership throughout this Co-Development – within an efficient timeframe.”

 Click here to read today’s ASX release.